Sign up
Pharma Capital

C4X Discovery Holdings plc

www.c4xdiscovery.com

Overview

Financials (in $m unless stated)
Sales 7.064
EBITDA -2.345
Operating Profit -2.533
Pre-tax Profit -2.526
Net Profit -1.135
Capex -0.044
Operating Cash Flow -0.416
Net Working Capital -0.045
Key Ratios
EBITDA Margin -0.332
Operating Profit Margin -0.359 -%
Net Profit Margin -0.161 -%
Capex/Sales (%) 0.006
NWC/Sales (%) -16.06738391846
Asset Turnover 0.737
Days Inventory 0.000  days
Days Receivable 2.506  days
Days Payable 0.000  days
Performance (Last 3 Years)
Sales CAGR 1.829
EBITDA CAGR n/a
Operating Profit CAGR -
Profit CAGR -
Return on Equity -0.132
Return on Assets -0.118
Return on Invested Capital (ROIC) -0.132
ROIC - WACC n/a
Valuation
Market Cap -
Price to Earnings 0.000
Price to Book Value 2.391
Price to Tangible Book -
Equity to FCF Yield -636.7816091954
Enterprise Value -
EV to Sales -
EV to EBITDA -
EV to Operating Profit -
EV to Invested Capital -
EV to FCF Yield -
SdsDividend Yield -
Payout Ratio 0.000000
Per SdsShare Data (in GBp unless stated)
Earnings per share -0.024391
Operating Cashflow per share -0.0089322476987867
Free Cashflow per share -0.034800
SdsDividend per share -
NAV per share -
Cash per share -0.033800
Solvency
Intangibles Incl. Excl.
Net debt to Equity % -68.240763396134 -85.173308902122
Cash to Equity % 68.240763396134 -162499931.75924
Gross debt to Equity % 0 0
Gross Debt < 1 Year to Equity 0 0
Net debt to Assets % 0 0
Net Debt/EBITDA 237.86780383795 -0
Net Interest Cover n/a
Op Cashflow Interest Cover n/a
Current Ratio 8.466513 n/a
Quick Ratio 6.456120 n/a
Cash Ratio - n/a (Intangibles collected as non-current)
SdsDividend Cover - n/a
Key Dates
Latest SdsDividend Pay date n/a
Latest Ex-SdsDividend date n/a
Last Annual SdsResults 2018-12-11
Last Interim SdsResults 2018-12-11

Profit/Lost

(Figures in m unless stated)31/07/1831/07/1731/07/1631/07/1531/07/1431/07/1331/07/12
Sales
Cost of Goods Sold
Gross Profit
Operating Expenses
EBITDA
Depreciation & Amortisation
EBIT (Operating Profit)
Interest Expense/Income
Profit Before Tax
Taxes on Income
Net Profit
Net Margin
Net profit/loss per share
Basic EPS
Diluted EPS

Balance sheet

 
(Figures in £m unless stated)
ASSETS
Tangible Assets
Intangible Assets
Investments
Total Fixed Assets
Stocks
Debtors
Cash & Equivalents
Total Current Assets
Other Assets n/a
Total Assets
LIABILITIES
Interest bearing debt < 1 year
Other Trade Creditors < 1 year
Total Creditors within 1 year
Interest bearing debt > 1 year
Other Trade Creditors > 1 year
Total Creditors > 1 year
Other Liabilities  n/a
Total Liabilities
Net Assets(NET Tangible Assets exist)
EQUITY
Called up share capital
Share Premium
Profit / loss
Other Equity
Shareholders Funds
Preference Stock
Total Capital Employed

Cash flow

Figures in $(m) unless stated 31/07/1831/07/1731/07/1631/07/1531/07/1431/07/1331/07/12
EBITDA
Change in Working Capital
Cash Taxes Paid
Cash Interest Paid/Received
Other (incl. non-cash items)
Net Cash from Operating Activities
Capital Expenditure
Acquisitions/Disposals
Other Investing Activities
Net Cashflow from Investing Activities
Dividends
Increase/Decrease in Debt
Increase/Decrease in Equity
Other Financing Activities
Cash from Financing
Net increase in cash

Directors dealings

Date Director Trans Amount Type Price(p) Value (£) Holding %
2019-03-06 P 40650.00 61.5 25000
2018-10-19 P 5900.00 86.7 5115
- - - - -
- - - - -
- - - - -
- - - - -
- - - - -
- - - - -
- - - - -
- - - - -
2018-04-17 P 60000.00 113 67800
2018-04-17 P 10000.00 108.5 10850
2018-04-16 P 20000.00 101.5 20300
- - - - -
- - - - -
- - - - -
- - - - -
- - - - -
- - - - -
- - - - -
- - - - -
- - - - -
2017-09-06 P 30000.00 75 22500
2017-09-06 P 98000.00 77.5 75950
- - - - -
- - - - -
- - - - -
- - - - -
- - - - -
- - - - -
2016-11-30 P 40000.00 97 38800
2016-09-27 P 465686.00 102 475000

Dividends

No data.

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.